CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching With Cutting-Edge Hi-C Technology
H.C. Wainwright Maintains CareDx(CDNA.US) With Hold Rating
CareDx Showcases Latest Advancements Across Its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting
CareDx Analyst Ratings
CareDx Faces Challenges Amid Disappointing Financial Performance and Overambitious Growth Targets, Warrants Sell Rating by Analyst
Goldman Sachs Maintains CareDx(CDNA.US) With Buy Rating, Raises Target Price to $35
Crude Oil Tumbles 5%; Goldman Sachs Earnings Top Views
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Express News | CareDx Inc: Performance Continues to Be Strong as We Head Into Q4
Express News | CareDx Inc: Q3 Revenue Is Expected to Be in Range of $82 Mln to $83 Mln
CareDx Reports Preliminary Financial Results for Third Quarter 2024
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Capitulation in Biotech Is Near, as Well as a Rally – Piper Sandler
CareDx Stock Climbs 7% Amid Reports Natera Not Pursuing Litigation
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating
CareDx Inc (CDNA) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Adjusted ...
CareDx Huang to Lead Key Data Science Initiatives >CDNA
Express News | CareDx Appoints Jing Huang Chief Data and AI Officer
BTIG Maintains CareDx(CDNA.US) With Buy Rating, Maintains Target Price $40
Buy Rating on CareDx: A Positive Outlook Amidst Legal Resolutions and Growth Potential